Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TSH BiopharmROCO:8432 +1.19%91 Return-on-Tangible-Equity is 15.89% as of Jun. 2026, which is 174% above its 10-year median of 5.79. GuruFocus rates ROCO:8432 with a GF Score™ of 91/100 and a GF Value™ of NT$71.54 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 897 Drug Manufacturers companies, TSH Biopharm ranks better than 69.68% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. TSH Biopharm's annualized net income for the quarter that ended in Jun. 2026 was NT$183 Mil. TSH Biopharm's average shareholder tangible equity for the quarter that ended in Jun. 2026 was NT$1,154 Mil. Therefore, TSH Biopharm's annualized Return-on-Tangible-Equity for the quarter that ended in Jun. 2026 was 15.89%.
The historical rank and industry rank for TSH Biopharm's Return-on-Tangible-Equity or its related term are showing as below:
ROCO:8432'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 4.28 Med: 5.79 Max: 14.78
Current: 14.78
During the past 13 years, TSH Biopharm's highest Return-on-Tangible-Equity was 14.78%. The lowest was 4.28%. And the median was 5.79%.
ROCO:8432's Return-on-Tangible-Equity is ranked better than 69.68% of 897
companies
in the Drug Manufacturers industry
Industry Median: 7.5
vs ROCO:8432: 14.78
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
TSH Biopharm Return-on-Tangible-Equity Related Terms
TSH Biopharm Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for TSH Biopharm's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:8432 vs ZTS: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, TSH Biopharm's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TSH Biopharm Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, TSH Biopharm's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where TSH Biopharm's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Jun. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 15.89% mean?
TSH Biopharm (ROCO:8432) has a Return-on-Tangible-Equity of 15.89% as of Jun. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on TSH Biopharm and its competitors. This is 174% above median its historical median of 5.79. Over the past decade, TSH Biopharm's Return-on-Tangible-Equity has ranged from 4.28 to 14.78. According to the industry distribution chart, TSH Biopharm ranks #272 out of 897 companies in the Drug Manufacturers industry, placing it in the top 30.3%.
Is TSH Biopharm's Return-on-Tangible-Equity too high?
TSH Biopharm's current Return-on-Tangible-Equity of 15.89% is 174% above median its 10-year median of 5.79. Over the past 10 years, this metric has ranged from a low of 4.28 to a high of 14.78. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.50. TSH Biopharm's value of 15.89% is 111.9% above this industry median. Based on the distribution chart, TSH Biopharm ranks #272 out of 897 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, TSH Biopharm has a GF Score™ of 91/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does TSH Biopharm's Return-on-Tangible-Equity compare to ZTS?
According to the Drug Manufacturers industry distribution chart, TSH Biopharm ranks #272 out of 897 companies for Return-on-Tangible-Equity. This puts TSH Biopharm in the upper half of its industry. The industry median Return-on-Tangible-Equity is 7.50. TSH Biopharm's value of 15.89% is 111.9% above this benchmark. Historically, TSH Biopharm's own Return-on-Tangible-Equity has ranged from 4.28 to 14.78 over the past decade. While the company's 10-year median is 5.79 vs. the industry median of 7.50, TSH Biopharm has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.50, based on 897 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TSH Biopharm's current Return-on-Tangible-Equity of 15.89% is 111.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on TSH Biopharm and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TSH Biopharm's current Return-on-Tangible-Equity is 15.89%, which is 174% above median its own 10-year median of 5.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TSH Biopharm stock overvalued right now?
Based on GuruFocus' analysis, TSH Biopharm (ROCO:8432) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$71.54, compared to a current price of NT$50.90 — trading 28.9% below its estimated fair value. The current Return-on-Tangible-Equity is 15.89%, which is 174% above median its 10-year median of 5.79 and 111.9% above the Drug Manufacturers industry median of 7.50. TSH Biopharm's overall GF Score™ is 91/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For TSH Biopharm (ROCO:8432), the current Return-on-Tangible-Equity is 15.89% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TSH Biopharm (ROCO:8432) Overvalued in 2026?
Based on GuruFocus' analysis, TSH Biopharm stock appears to be undervalued.
The current stock price of NT$50.90 is trading 28.9% below its estimated GF Value™ of NT$71.54.
GuruFocus considers TSH Biopharm to be Modestly Undervalued.
Key valuation signals for ROCO:8432:
Return-on-Tangible-Equity: 15.89% (174% above median its 10-year median of 5.79)
GF Value™: NT$71.54 vs. price of NT$50.90 (28.9% below fair value)
Industry Position: 111.9% above the Drug Manufacturers median (#272 of 897)
No single metric tells the full story. See the ROCO:8432 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TSH Biopharm Corp Ltd is engaged in sale of a variety of pharmaceuticals, chemical drugs and engaged in biotechnology services. The company specializes in the development, manufacture, and marketing of branded drugs for chronic diseases. Key therapeutic areas include cardiovascular, central nervous system, gastroenterology, and severe chronic diseases, alongside precision medicine/genetic testing services .The Company's revenue is earned domestically. It earns majority of its revenue from the sale of Lozenges.
91GF Score
Get the complete analysis for ROCO:8432
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:8432 has been successfully added to your 
